THE RENIN-ANGIOTENSIN SYSTEM (RAS) has been one of the most extensively studied endocrine control systems in humans. It harks back to the discovery by Tigerstedt and Bergman in 1898 that renin, a kidney extract, increases blood pressure (6, 9). The RAS also functions as an autocrine/paracrine control system within various organs, such as the heart, kidney, and brain (2). More recently, another RAS control system, the intracrine RAS, has come to light (3). Here, it appears that ANG II is either internalized or synthesized by various cells, where it has been reported to bind to intracellular angiotensin type 1 (AT 1 )-like receptors, presumably to effect functional responses. Little is known regarding these mechanisms, and what is known constitutes considerable dialogue and debate. It seems that we are only beginning to understand the extent of RAS's regulatory role in the physiological function of the organism.
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In this issue of American Journal of Physiology-Cell Physiology, Deliu, Brailiou, and colleagues (1) take an initial step toward understanding the mechanisms by reporting on a novel, intracrine control mechanism by RAS in hypothalamic neurons. The authors rightly point out that such intracrine control most likely exists in hypothalamic neurons because of the evidence of neuronal synthesis of angiotensinogen and generation of ANG II in hypothalamic nuclei (3, 8) . However, little, if any, evidence in the current literature supports the physiological relevance or mechanisms for intracrine RAS in neurons. The authors provide compelling evidence that begins to fill this void.
Deliu et al.
(1) utilized concurrent Ca 2ϩ and voltage imaging to examine the functionality of intracellular AT 1 receptors in primary cultures of hypothalamic neurons obtained from neonatal rats. First, important control measurements were performed to validate the assay and to rule out false-positives due to reagents alone. Controls comprised U2OS (human osteosarcoma) cells (7) In summary, this is largely a pharmacological investigation, and caveat emptor is appropriate, considering the limited specificity of all pharmacological inhibitors. Nevertheless, this is an important study that elucidates an intracrine mechanism for RAS action in hypothalamic neurons. These exciting findings provide impetus for Deliu et al. and others to explore more of this RAS function in hypothalamic neurons with molecular biological reagents that target signaling pathways with greater specificity.
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